loading page

Palmitoylation of Tetraspanin CD82 Is Required for Its Biological Activities of Anti-apoptosis in Breast Cancer
  • +5
  • Yu Zhang,
  • Shuiqing He,
  • Jingya Bu,
  • Mingzhe Zhang,
  • Yihuan Zhang,
  • Yaning Yu,
  • Xiaodan Wang,
  • Ying Li
Yu Zhang
Second Affiliated Hospital of Dalian Medical University
Author Profile
Shuiqing He
Second Affiliated Hospital of Dalian Medical University
Author Profile
Jingya Bu
Second Affiliated Hospital of Dalian Medical University
Author Profile
Mingzhe Zhang
Second Affiliated Hospital of Dalian Medical University
Author Profile
Yihuan Zhang
Second Affiliated Hospital of Dalian Medical University
Author Profile
Yaning Yu
Second Affiliated Hospital of Dalian Medical University
Author Profile
Xiaodan Wang
Second Affiliated Hospital of Dalian Medical University
Author Profile
Ying Li
Second Affiliated Hospital of Dalian Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Background: CD82/KAI-1 which is a member of the tetraspanin superfamily, has been proposed to exert its activity via the Tetraspanin Web. However, the mechanism of CD82 palmitoylation in this web has not been fully elucidated. The purpose of this study is to investigate cell migration and apoptosis by mutation of tetraspanin CD82 palmitoylation. Methods: This study elucidated the impact of various palmitoylation site mutations on apoptosis in breast cancer cells through a comprehensive approach involving RT-PCR, Western blotting, TUNEL assay, immunofluorescence, and tumor formation assay in athymic nude mice model. Results: We found that the mutation of CD82 palmitoylation at cys74 and cys83 or cys5 and cys74 and cys83 simultaneously increased apoptosis in breast cancer. However, the other forms of mutation of CD82 palmitoylation showed no effects on apoptosis. Conclusion: The study strongly implicate that CD82 palmitoylation at cys74 and cys83 are both closely related to maintain biological function.
21 May 2023Submitted to Cancer Reports
29 May 2023Assigned to Editor
29 May 2023Submission Checks Completed
29 May 2023Review(s) Completed, Editorial Evaluation Pending
04 Jun 2023Reviewer(s) Assigned
21 Jun 2023Editorial Decision: Revise Major